Infomerics Valuation and Rating Private Limited

iSERA Lifesciences submits Q4 FY26 monitoring report showing minimal utilization of its ₹8.08 crore rights issue proceeds. Only ₹0.20 crore (2.47%) was utilized for issue expenses and general corporat